7 Fastest Growing European Stocks to Invest In
European stocks are getting a closer look again, and not only because investors want to diversify away from a crowded U.S. trade.
Ascendis Pharma A/S (ASND)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 10,281,496 | $2,192,426,207 | 22.46% | |
| 2. | VenBio Select Advisor Kurt Von Emster | 5,111,111 | $1,089,893,310 | +1% | 10.71% |
| 3. | Perceptive Advisors Joseph Edelman | 1,081,421 | $230,602,214 | -1% | 4.11% |
| 4. | Citadel Investment Group Ken Griffin | 519,516 | $110,781,591 | +1780% | 0.02% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 370,473 | $78,999,663 | -57% | 0.31% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 458,000 | $671,886 | 0.09% | |
| 2. | 1,451 | $332,000 | 0.2% | |
| 3. | 957 | $218,895 | 0.01% | |
| 4. | 700 | $160,141 | 0% | |
| 5. | 635 | $144,932 | 0% |
News See All
Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth
Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years.
10 Best NASDAQ Growth Stocks to Buy for the Next 2 Years
On February 19, Tom Lee of Fundstrat and BitMine joined 'Closing Bell' on CNBC to talk about the state of the markets.
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2025 Earnings Call Transcript
Operator: At this time, participants are in listen-only mode. Thank you for standing by, and welcome to the Ascendis Pharma A/S Fourth Quarter 2025 Earnings Conference Call.
RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets
Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best high growth European stocks to buy.
BofA Reiterates Buy Rating on Ascendis Pharma (ASND) While Wells Fargo Analyst Raises PT
In other news, on January 20, TheFly reported that Wells Fargo analyst Derek Archila upgraded the price target on Ascendis Pharma from $322 to $330, keeping an Overweight rating on the stock.
11 Best Stocks to Buy for Investment
Following growing uncertainty in global markets amid heightened geopolitical tensions, the U.S. market rebounded this week.
10 High Growth European Stocks To Buy
European equities began the last week of January in a sour mood, with investors concerned on January 26 about rising geopolitical tensions in anticipation of a Federal Reserve policy meeting and a flood...
Ascendis Pharma A/S (ASND): A Bull Case Theory
We came across a bullish thesis on Ascendis Pharma A/S on Tip Ranks’ YouTube Channel. In this article, we will summarize the bulls’ thesis on ASND.
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2025 Earnings Call Transcript
Operator: Good day, and welcome to the Third Quarter 2025 Pharma Earnings Conference Call. At this time, participants are in a listen-only mode.
Hedge Fund Resource Center